Abstract 97P
Background
Myocarditis is a rare adverse effect of immune-checkpoint inhibitor therapy (ICI) associated with a high fatality rate and no clear predeterminants. European Society of Cardiology suggests baseline cardiac assessment and serial monitoring with ICI treatment. The volume of investigations recommended has been a barrier to adoption in practice.
Methods
We conducted a prospective study of clinical utility of baseline and serial cardiac assessment in a UK tertiary hospital. Patients were risk stratified by cardiac history, risk factors, baseline bloods including cardiac biomarkers and cardiac investigations, repeated at 3-4 weeks and 6-8 weeks. Aims; test feasibility; assess the value in risk stratifying patients to predict risk; determine if serial monitoring identified early cardiac toxicity.
Results
175 patients, 86 High risk, 89 Low risk. 8/175 patients baseline troponin >30. 28/175 patients baseline BNP >400. 2 patients had a troponin rise at 3-4 week, neither developed cardiotoxicity. 7 developed a troponin rise at 6-8 weeks, none developed cardiotoxicity. 32 patients had a BNP rise at 3-4 weeks. 9 significant. 1 patient BNP increased to >1000 without cardiotoxicity. 5 patients BNP approximately doubled; 2 patients rose >1000, 1 without cardiotoxicity, 1 who developed myocarditis later. 2 symptomatic patients with raised biomarkers and were treated for cardiotoxicity. 1 presented in SVT, LVEF 33%, CMR negative for myocarditis. 1 with syncopal episodes. In both cases biomarkers reduced on steroids, ICI was terminated.
Conclusions
All patients who developed cardiotoxicity were screened as high risk. 2 patients with cardiotoxicity were identified through clinical assessment not serial monitoring. Interpretation of cardiac biomarkers should accompany careful clinical assessment and liaison with cardiology. Baseline assessment supports decision making. Risk stratification may be a way to streamline monitoring.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
Resources:
Abstract
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
Resources:
Abstract
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
Resources:
Abstract
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
Resources:
Abstract
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
Resources:
Abstract
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
Resources:
Abstract
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
Resources:
Abstract
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
Resources:
Abstract
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract